Abzena company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Founded Year



Unattributed VC - II | Alive

Total Raised


Last Raised

$65M | 2 mos ago

About Abzena

Abzena is focused on providing proprietary technologies and value-added services to enable the development of better biopharmaceuticals. Abzena is comprised of two wholly-owned subsidiary businesses: PolyTherics and Antitope, which have established a broad suite of complementary technologies that are designed to improve the chances of successful development of antibodies and proteins with enhanced therapeutic benefits. PolyTherics specializes in proprietary site-specific conjugation technologies for antibody-drug conjugate development and solutions for the optimization of the therapeutic properties of biopharmaceuticals. Antitope focuses on immunogenicity assessment, protein engineering to create humanized antibodies and deimmunized therapeutic proteins, and cell line development for manufacture. Abzena was founded in 2001 and is based in London, England.

Abzena Headquarter Location

Babraham Research Campus, Babraham

London, England, CB22 3AT,

United Kingdom

+44 1223 903498

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Abzena

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Abzena is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Abzena Patents

Abzena has filed 1 patent.

The 3 most popular patent topics include:

  • Antineoplastic drugs
  • Experimental cancer drugs
  • Immunology
patents chart

Application Date

Grant Date


Related Topics



Experimental cancer drugs, Monoclonal antibodies, Immunology, Monoclonal antibodies for tumors, Antineoplastic drugs


Application Date


Grant Date


Related Topics

Experimental cancer drugs, Monoclonal antibodies, Immunology, Monoclonal antibodies for tumors, Antineoplastic drugs



Latest Abzena News

Expanding Operations in Biologics

Apr 19, 2022

To embed, copy and paste the code into your website or blog: <iframe frameborder="1" height="620" scrolling="auto" src="//www.jdsupra.com/post/contentViewerEmbed.aspx?fid=edf3ba9e-bb6f-401b-93b0-4ae745bb190f" style="border: 2px solid #ccc; overflow-x:hidden !important; overflow:hidden;" width="100%"></iframe> Catalent and Abzena both recently announced substantial investments into new biologics facilities. Catalent is spending up to $160 million to build a new manufacturing facility near Oxford, UK. Catalent plans to equip the facility with “state-of-the-art capabilities for the development and manufacture of biologic therapies and vaccines, including mRNA, proteins and other advanced modalities,” and hopes to start servicing customer programs from the new facility before the end of 2022. According to Catalent, it has expertise in biosimilar development and manufacturing , with multiple biosimilar products on the market utilizing its technology. Abzena’s new facility just opened and is in the U.S., near Abzena’s manufacturing center in San Diego. The new facility is focused on biologics testing and will offer “Abzena’s partners access to cell-based and PCR safety assays; and viral clearance studies to support their IND, IMPD, BLA and MAA applications.”  According to Abzena, with this latest investment, it now offers “all services appropriate for research cell banks, characterization of master and working cell banks, end-of-production of cell cultures, and bulk drug substances.”  Abzena had announced last year  that it had partnered with BioXpress Therapeutics to support the development and manufacture of biosimilars for global customers. The opening of the new facility marks Abzena’s sixth site across the globe.

Abzena Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Abzena Rank

  • When was Abzena founded?

    Abzena was founded in 2001.

  • Where is Abzena's headquarters?

    Abzena's headquarters is located at Babraham Research Campus, Babraham, London.

  • What is Abzena's latest funding round?

    Abzena's latest funding round is Unattributed VC - II.

  • How much did Abzena raise?

    Abzena raised a total of $108.57M.

  • Who are the investors of Abzena?

    Investors of Abzena include Biospring Partners, WCAS, Welsh Carson Anderson & Stowe, Touchstone Innovations, Abzena and 11 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.